Published in Proc Natl Acad Sci U S A on November 26, 2008
Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol (2013) 4.33
Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature (2011) 3.80
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A (2011) 2.65
FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol (2010) 2.44
Structure and function of immunoglobulins. J Allergy Clin Immunol (2010) 2.22
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med (2012) 2.05
IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 1.95
Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med (2012) 1.93
A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol (2010) 1.84
General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A (2013) 1.69
NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry (2012) 1.60
Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum (2010) 1.52
Maternal vaccination: moving the science forward. Hum Reprod Update (2014) 1.50
Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun (2015) 1.50
Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J Am Chem Soc (2012) 1.44
Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol (2009) 1.42
Intravenous immunoglobulins--understanding properties and mechanisms. Clin Exp Immunol (2009) 1.34
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol (2013) 1.31
NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat Chem Biol (2011) 1.30
Unraveling the autoimmune translational research process layer by layer. Nat Med (2012) 1.27
Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics (2011) 1.20
Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J Immunol (2014) 1.19
Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation (2010) 1.18
Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc Natl Acad Sci U S A (2013) 1.17
Puzzling inefficiency of H5N1 influenza vaccines in Egyptian poultry. Proc Natl Acad Sci U S A (2010) 1.17
Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One (2012) 1.16
Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor. J Am Chem Soc (2011) 1.14
The challenge and promise of glycomics. Chem Biol (2014) 1.13
The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol (2012) 1.11
Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. J Autoimmun (2015) 1.11
Emerging technologies for making glycan-defined glycoproteins. ACS Chem Biol (2011) 1.11
Multiple mechanisms of immune suppression by B lymphocytes. Mol Med (2012) 1.08
Emerging antibody products and Nicotiana manufacturing. Hum Vaccin (2011) 1.08
Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One (2011) 1.07
Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci Rep (2014) 1.06
T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. J Clin Invest (2013) 1.06
Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun (2012) 1.05
Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A (2015) 1.03
Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol (2014) 1.02
Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care (2012) 1.00
Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics (2014) 0.99
Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology (2015) 0.99
Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell (2015) 0.99
Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics (2011) 0.99
Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1. Circ Res (2012) 0.98
Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathog (2011) 0.98
Marginal zone B cells regulate antigen capture by marginal zone macrophages. J Immunol (2011) 0.96
Tolerance: an overview and perspectives. Nat Rev Nephrol (2010) 0.95
Infection, inflammation and host carbohydrates: a Glyco-Evasion Hypothesis. Glycobiology (2012) 0.95
In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol (2012) 0.95
DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Natl Acad Sci U S A (2009) 0.94
Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol (2010) 0.94
Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G. PLoS One (2013) 0.94
DC-SIGN activation mediates the differential effects of SAP and CRP on the innate immune system and inhibits fibrosis in mice. Proc Natl Acad Sci U S A (2015) 0.94
The regulatory power of glycans and their binding partners in immunity. Trends Immunol (2013) 0.93
Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest (2015) 0.91
Chemical and chemoenzymatic synthesis of glycoproteins for deciphering functions. Chem Biol (2014) 0.91
In vivo veritas: the surprising roles of Fc receptors in immunity. Nat Immunol (2010) 0.91
Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G. Glycoconj J (2012) 0.91
Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. MAbs (2013) 0.91
Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol (2010) 0.90
Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases. Crit Rev Immunol (2013) 0.90
Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation. J Allergy Clin Immunol (2015) 0.90
SIGN-R1, a C-type lectin, enhances apoptotic cell clearance through the complement deposition pathway by interacting with C1q in the spleen. Cell Death Differ (2012) 0.89
The other side of immunoglobulin G: suppressor of inflammation. Clin Exp Immunol (2009) 0.89
Highly parallel characterization of IgG Fc binding interactions. MAbs (2014) 0.89
EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycans. Glycobiology (2015) 0.88
Potential application of tregitopes as immunomodulating agents in multiple sclerosis. Neurol Res Int (2011) 0.88
Adult invasive and noninvasive infections due to Streptococcus dysgalactiae subsp. equisimilis in France from 2006 to 2010. J Clin Microbiol (2013) 0.88
Mechanisms of tolerance induction in allergic disease: integrating current and emerging concepts. Clin Exp Allergy (2013) 0.88
Anti-inflammatory IgG production requires functional P1 promoter in β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) gene. J Biol Chem (2012) 0.88
Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc Natl Acad Sci U S A (2015) 0.87
Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease. Hum Vaccin Immunother (2012) 0.87
Polymeric human Fc-fusion proteins with modified effector functions. Sci Rep (2011) 0.86
B Cells, Antibodies, and More. Clin J Am Soc Nephrol (2015) 0.85
Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? Rheumatol Int (2010) 0.85
Autoantibodies targeting tumor-associated antigens in metastatic cancer: Sialylated IgGs as candidate anti-inflammatory antibodies. Oncoimmunology (2013) 0.84
Immunoglobulin G: a potential treatment to attenuate neuroinflammation following spinal cord injury. J Clin Immunol (2010) 0.84
Production of α2,6-sialylated IgG1 in CHO cells. MAbs (2015) 0.84
Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants. PLoS One (2015) 0.83
Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation (2013) 0.83
Retracted Dominant suppression of inflammation by glycan-hydrolyzed IgG. Proc Natl Acad Sci U S A (2013) 0.83
The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade. J Clin Immunol (2012) 0.83
Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. Sci Rep (2014) 0.83
Antibodies and their receptors: different potential roles in mucosal defense. Front Immunol (2013) 0.82
Fc glycan-modulated immunoglobulin G effector functions. J Clin Immunol (2014) 0.82
Impact of Glycosylation on Effector Functions of Therapeutic IgG. Pharmaceuticals (Basel) (2010) 0.81
Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice. Arthritis Res Ther (2012) 0.81
Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye. Front Immunol (2015) 0.81
IgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a fab-Peptide sequence. PLoS One (2014) 0.81
B-cell-independent sialylation of IgG. Proc Natl Acad Sci U S A (2016) 0.81
A perspective on the structure and receptor binding properties of immunoglobulin G Fc. Biochemistry (2015) 0.80
Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants. Proc Natl Acad Sci U S A (2015) 0.80
Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus. Bone Marrow Transplant (2015) 0.80
DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease. Pediatr Rheumatol Online J (2013) 0.79
Sphingosine 1-Phosphate Receptor 3-Deficient Dendritic Cells Modulate Splenic Responses to Ischemia-Reperfusion Injury. J Am Soc Nephrol (2015) 0.79
B cells with regulatory properties in transplantation tolerance. World J Transplant (2015) 0.78
Macrophage heterogeneity in lymphoid tissues. Semin Immunopathol (2013) 0.78
Immunoglobulins drive terminal maturation of splenic dendritic cells. Proc Natl Acad Sci U S A (2013) 0.78
RAG-1-deficient mice have no mature B and T lymphocytes. Cell (1992) 20.97
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 14.43
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell (2000) 8.34
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13
FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell (1994) 7.66
Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (2005) 6.48
Organ-specific disease provoked by systemic autoimmunity. Cell (1996) 6.44
Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med (2003) 5.58
Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature (1996) 5.25
The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol (2007) 4.96
Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science (2001) 4.62
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (2008) 4.11
Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development (1994) 3.86
DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J Exp Med (2003) 3.32
Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol (2003) 3.25
Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol (2008) 3.05
Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol (2007) 2.43
Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages. Cell (1995) 2.34
Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity (2003) 2.20
Role of the scavenger receptor MARCO in alveolar macrophage binding of unopsonized environmental particles. J Exp Med (1999) 2.08
Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med (2006) 2.00
The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide of Streptococcus pneumoniae in the marginal zone of mouse spleen. Proc Natl Acad Sci U S A (2003) 1.91
SIGN-R1, a novel C-type lectin expressed by marginal zone macrophages in spleen, mediates uptake of the polysaccharide dextran. Int Immunol (2003) 1.90
DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood (2006) 1.89
The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med (2007) 1.84
Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages. EMBO J (1991) 1.79
Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int Immunol (2001) 1.74
SIGN-R1 contributes to protection against lethal pneumococcal infection in mice. J Exp Med (2004) 1.73
Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet (1993) 1.72
Widely divergent biochemical properties of the complete set of mouse DC-SIGN-related proteins. J Biol Chem (2006) 1.65
High and low affinity carbohydrate ligands revealed for murine SIGN-R1 by carbohydrate array and cell binding approaches, and differing specificities for SIGN-R3 and langerin. Int Immunol (2004) 1.58
CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat Med (2007) 1.57
Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol (2007) 1.57
Immune escape through C-type lectins on dendritic cells. Trends Immunol (2002) 1.30
Protective mechanisms of IVIG. Curr Opin Immunol (2007) 1.07
Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J Immunol Methods (2005) 1.01
A new mouse model of rheumatoid arthritis: organ-specific disease provoked by systemic autoimmunity. Ryumachi (1997) 0.93
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13
Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (2005) 6.48
Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60
FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity (2005) 4.22
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (2008) 4.11
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature (2011) 3.80
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med (2004) 3.56
Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol (2008) 3.05
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science (2011) 2.63
Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med (2002) 2.54
TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med (2006) 2.44
Fc-receptors as regulators of immunity. Adv Immunol (2007) 2.38
Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. J Exp Med (2003) 2.23
Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A (2005) 2.22
Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity (2003) 2.20
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest (2005) 2.10
Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med (2006) 2.00
The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol (2004) 1.95
Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci U S A (2006) 1.91
Antibodies, Fc receptors and cancer. Curr Opin Immunol (2007) 1.89
Antibody-mediated modulation of immune responses. Immunol Rev (2010) 1.84
A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol (2010) 1.84
The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med (2007) 1.84
Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J Exp Med (2010) 1.83
Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science (2005) 1.81
Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med (2006) 1.81
Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med (2002) 1.77
General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A (2013) 1.69
Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A (2007) 1.66
WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood (2008) 1.65
Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Natl Acad Sci U S A (2012) 1.62
Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood (2005) 1.55
Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus. J Exp Med (2007) 1.53
FcγRs in health and disease. Curr Top Microbiol Immunol (2011) 1.51
Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med (2007) 1.51
Novel roles for the IgG Fc glycan. Ann N Y Acad Sci (2012) 1.51
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A (2010) 1.46
In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A (2008) 1.44
Marginal zone macrophages suppress innate and adaptive immunity to apoptotic cells in the spleen. Blood (2011) 1.42
Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 1.37
Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol (2007) 1.34
Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur J Immunol (2007) 1.32
Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A (2008) 1.31
A mouse model for HIV-1 entry. Proc Natl Acad Sci U S A (2012) 1.23
Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. Blood (2009) 1.23
Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity (2002) 1.19
Analyzing antibody-Fc-receptor interactions. Methods Mol Biol (2008) 1.19
Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J Immunol (2013) 1.14
AIRE regulates T-cell-independent B-cell responses through BAFF. Proc Natl Acad Sci U S A (2008) 1.13
TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol (2012) 1.13
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest (2016) 1.12
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc Natl Acad Sci U S A (2012) 1.11
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res (2003) 1.11
Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med (2010) 1.10
Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol (2008) 1.08
Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res (2002) 1.08
IL-18 in inflammatory and autoimmune disease. Cell Mol Life Sci (2013) 1.06
Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun (2012) 1.05
Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J Immunol (2008) 1.04
FcgammaRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. J Immunol (2008) 1.03
A novel B cell-mediated transport of IgE-immune complexes to the follicle of the spleen. J Immunol (2008) 1.01
Fcgamma receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice. Arthritis Rheum (2009) 1.00
Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol (2008) 1.00
A regulatory role for macrophage class A scavenger receptors in TLR4-mediated LPS responses. Eur J Immunol (2010) 0.97
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood (2003) 0.96
Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo. Proc Natl Acad Sci U S A (2013) 0.96
Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J Clin Invest (2014) 0.95
A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle (2012) 0.94
Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Cancer Res (2004) 0.94
New nomenclature for Fc receptor-like molecules. Nat Immunol (2006) 0.94
BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses. J Immunol (2012) 0.93
Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice. J Exp Med (2005) 0.93
Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis. Am J Pathol (2003) 0.92
IL-18 skews the invariant NKT-cell population via autoreactive activation in atopic eczema. Eur J Immunol (2009) 0.92
The inflammatory cytokine IL-18 induces self-reactive innate antibody responses regulated by natural killer T cells. Proc Natl Acad Sci U S A (2011) 0.89
Independent expansion of epitope-specific plasma cell responses upon HIV-1 envelope glycoprotein immunization. J Immunol (2013) 0.86
Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant. J Immunol (2011) 0.86
Inhibitory Fcγ receptor is required for the maintenance of tolerance through distinct mechanisms. J Immunol (2014) 0.85
Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling. Proc Natl Acad Sci U S A (2013) 0.85
An anatomical view on macrophages in tolerance. Autoimmun Rev (2009) 0.84
Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol (2013) 0.84
A critical role for Fc gamma RIIB in the induction of rheumatoid factors. J Immunol (2004) 0.82
The expression of BAFF, APRIL and TWEAK is altered in eczema skin but not in the circulation of atopic and seborrheic eczema patients. PLoS One (2011) 0.81
humanized mice to study FcγR function. Curr Top Microbiol Immunol (2014) 0.81
Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease. Am J Pathol (2007) 0.81